Hematology PGx.
Know your clotting risk. A gene panel for medications used to treat low platelet counts (thrombocytopenia), including inherited clotting risk factors. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
3 genes · CYP2C9, FII, FV
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Panel medications.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Avatrombopag — CYP2C9
Poor CYP2C9 metabolizers reach higher drug levels and need lower doses.
Avatrombopag, lusutrombopag — FV, FII
Inherited clotting variants (Factor V Leiden, prothrombin) matter when a treatment raises platelet counts — raising platelets raises clot risk too.
Who this is for
Drug metabolism and inherited clotting variants can both affect safety.
Low platelet count
Starting treatment for thrombocytopenia, where dose and clot risk both depend on genotype.
A procedure ahead
Platelet-raising treatment before a procedure is a common point to have the result in hand.
A clotting history
FV and FII results document inherited thrombosis risk for you and your relatives.
Is this test right for you?
You have a low platelet count and are starting treatment.
You are scheduled for a procedure that requires raising platelets.
You or close relatives have had blood clots.
You take other medications processed by CYP2C9.
Your hematologist suggested genetic testing.
You want results you can keep for future prescriptions.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Platelet-raising drugs (TPO receptor agonists) work by design — but higher platelet counts also raise clot risk, and both avatrombopag and lusutrombopag carry that warning in their labels. Inherited thrombophilia such as Factor V Leiden and the prothrombin FII variant changes baseline clot risk, while CYP2C9 status changes how much avatrombopag you absorb. The panel answers both questions in one sample.
1 in 20
of people of European ancestry carry Factor V Leiden, the most common inherited clotting variant.
Source: MedlinePlus Genetics
About 1 in 50
carry the prothrombin (FII) G20210A variant in European populations — the second major inherited clotting risk.
Source: MedlinePlus Genetics
3–8×
increased baseline venous-clot risk for people carrying one Factor V Leiden copy, compared with non-carriers.
Source: Genetics reviews of thrombophilia
≈2×
higher avatrombopag exposure in CYP2C9 poor metabolizers — the reason labels advise dose reduction.
Source: FDA avatrombopag labeling
How often should you test?
Test once — your genotype doesn't change. The highest-value moment is before starting a platelet-raising treatment or before a procedure where platelets need to be raised, especially if you or close relatives have had blood clots.
References
- MedlinePlus Genetics — Factor V Leiden thrombophilia: prevalence and venous clot risk.
- MedlinePlus Genetics — Prothrombin thrombophilia (FII G20210A).
- U.S. National Library of Medicine, DailyMed — avatrombopag prescribing information: CYP2C9 dosing and thrombosis warnings.
- U.S. National Library of Medicine, DailyMed — lusutrombopag prescribing information: thrombosis warnings.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Questions people actually ask
Bring data to your next hematology visit.
One sample, one flat price, a report your prescribers can refer back to.